284 related articles for article (PubMed ID: 15452897)
21. Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma.
Davidson B; Shih IeM; Wang TL
Hum Pathol; 2008 Nov; 39(11):1630-6. PubMed ID: 18656238
[TBL] [Abstract][Full Text] [Related]
22. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling.
Davidson B; Espina V; Steinberg SM; Flørenes VA; Liotta LA; Kristensen GB; Tropé CG; Berner A; Kohn EC
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):791-9. PubMed ID: 16467090
[TBL] [Abstract][Full Text] [Related]
23. Malignant pleural and pericardial effusion in invasive breast cancer: impact of the site of the primary tumor.
Pokieser W; Cassik P; Fischer G; Vesely M; Ulrich W; Peters-Engl C
Breast Cancer Res Treat; 2004 Jan; 83(2):139-42. PubMed ID: 14997044
[TBL] [Abstract][Full Text] [Related]
24. Significance of pericellular lacunae in cell blocks of effusions.
Price BA; Ehya H; Lee JH
Acta Cytol; 1992; 36(3):333-7. PubMed ID: 1580117
[TBL] [Abstract][Full Text] [Related]
25. [Diagnostic characteristics of the CA-50 and CA 72-4 tumor markers in body fluids. Use in the diagnosis of malignant effusions].
Lemberger J; Libman E; Lászlo-Klein M; Skenderović S; Novak A
Med Pregl; 1991; 44(3-4):126-9. PubMed ID: 1921859
[TBL] [Abstract][Full Text] [Related]
26. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
Davidson B; Elstrand MB; McMaster MT; Berner A; Kurman RJ; Risberg B; Trope CG; Shih IeM
Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
[TBL] [Abstract][Full Text] [Related]
28. Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma.
Kleinberg L; Dong HP; Holth A; Risberg B; Trope' CG; Nesland JM; Flørenes VA; Davidson B
Hum Pathol; 2009 Jun; 40(6):795-806. PubMed ID: 19157506
[TBL] [Abstract][Full Text] [Related]
29. Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors.
Yuan Y; Leszczynska M; Konstantinovsky S; Tropé CG; Reich R; Davidson B
Diagn Cytopathol; 2011 Aug; 39(8):562-6. PubMed ID: 20730893
[TBL] [Abstract][Full Text] [Related]
30. [Late pulmonary manifestation of ovarian and breast cancer--which contribution provide immunohistochemical techniques?].
Haidl P; Riffelmann FW; Kemper P; Köhler D; Müller KM
Pneumologie; 2002 Feb; 56(2):108-12. PubMed ID: 11842349
[TBL] [Abstract][Full Text] [Related]
31. Malignant effusions are sources of fibronectin and other promigratory and proinvasive components.
Kohn EC; Travers LA; Kassis J; Broome U; Klominek J
Diagn Cytopathol; 2005 Nov; 33(5):300-8. PubMed ID: 16240400
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions.
Lonardi S; Manera C; Marucci R; Santoro A; Lorenzi L; Facchetti F
Diagn Cytopathol; 2011 May; 39(5):313-7. PubMed ID: 21488172
[TBL] [Abstract][Full Text] [Related]
33. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
34. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
Zhu W; Michael CW
Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
[TBL] [Abstract][Full Text] [Related]
35. Immunocytochemical detection of ovarian carcinoma cells in serous effusions.
Cuijpers VM; Boerman OC; Salet van de Pol MR; Vooijs GP; Poels LG; Ramaekers FC
Acta Cytol; 1993; 37(3):272-9. PubMed ID: 8498129
[TBL] [Abstract][Full Text] [Related]
36. [Management of malignant pleural effusions].
Loddenkemper R
Pneumologie; 2005 Feb; 59(2):120-35. PubMed ID: 15724226
[TBL] [Abstract][Full Text] [Related]
37. New diagnostic and molecular characteristics of malignant mesothelioma.
Davidson B
Ultrastruct Pathol; 2008; 32(6):227-40. PubMed ID: 19117264
[TBL] [Abstract][Full Text] [Related]
38. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
Young RH
Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
[TBL] [Abstract][Full Text] [Related]
39. Differential diagnosis of malignant and reactive cells from serous effusions: image and texture analysis study.
García-Bonafé M; Moragas A
Anal Cell Pathol; 1996 Nov; 12(2):85-98. PubMed ID: 8986293
[TBL] [Abstract][Full Text] [Related]
40. [Cytological exam of the pleural fluid in the diagnosis of neoplastic pleuritis. Cases contribution].
Vignale L; Galli G; Rossi PC; Parentini GC
Minerva Med; 1990 Jun; 81(6):455-9. PubMed ID: 2359501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
